Tilray (TLRY)

Executive Summary

Tilray Brands, Inc. (NASDAQ: TLRY) is a leading global cannabis-lifestyle and consumer packaged goods company headquartered in Canada. Its core operations span the cultivation, processing, and distribution of medical and adult-use cannabis, and it has diversified into branded beverages, food, and wellness products. With a strong distribution network across multiple international markets, Tilray leverages its agricultural and processing capabilities to support both its commercial and biotech divisions. The biotech segment focuses on developing pharmaceutical cannabinoid-based therapies, with a pipeline of eight drug candidates targeting oncology, neurology, and inflammatory conditions. Tilray's clinical pipeline includes several completed early-stage trials, such as TN-TC11G for glioblastoma (Phase 1/2 completed November 2025) and TIL-TC150 for epilepsy (Phase 1). A Phase 3 trial of CBD for anxiety disorders remains in unknown status. Despite no approved pharmaceutical products to date, the company continues to advance its research and regulatory engagements. Tilray's public market valuation stands at approximately $662 million, reflecting its mixed profile as both a CPG player and an emerging biotech. Key upcoming catalysts include potential US cannabis rescheduling, data readouts from completed trials, and expansion into European medical cannabis markets.

Upcoming Catalysts (preview)

• 2026US DEA Rescheduling of Cannabis50% success
• H2 2026Data Publication or Regulatory Update from TN-TC11G Glioblastoma Trial40% success
• 2026European Medical Cannabis Market Expansion60% success